5 results
To assess the safety and biodistribution of 89Zr-pembrolizumab and its uptake in tumor and target irAE tissues
We will develop a bi-daily low-dose metronomic treatment schedule with paclitaxel in a convenient oral formulation and test whether this therapy has significant anti-angiogenic and anti-tumor activity.
Primary objectives: To explore the safety, feasibility, and the immune-activating capacity of different schemes of continuous/intermittent dabrafenib+trametinib during treatment with pembrolizumab as compared to pembrolizumab monotherapySecondary…
Objective- To evaluate anti-tumor activity of pembrolizumab (MK-3475) by evaluating the absence of high risk NMIBC or progressive disease in subjects with CIS at baseline (cohort A) and subjects without CIS at baseline (cohort B).Hypotheses:-…
To compare disease free and overall survival of RCC patients, after adjuvant treatment with pembrolizumab after surgical renal resection. The objective of the study is to demonstrate that treatment with pembrolizumab, in comparison to placebo, will…